When it comes to managing type 2 diabetes, there are plenty of options available in the market. This makes it challenging to determine which medication is the most effective and safe. Two popular options that have garnered attention in recent years are Farxiga vs Invokana.
However, what sets them apart in terms of effectiveness and safety? In this comparison, we will delve deep into the mechanisms of these two medications to help you make an informed decision. Read on.
Mechanism of Action
Farxiga and Invokana both work by inhibiting the SGLT2 protein in the kidneys. SGLT2 plays a key role in transporting glucose from urine back into the bloodstream. These medications work by inhibiting this protein, thereby promoting increased glucose elimination.
This leads to a reduction in blood sugar levels. This mechanism also offers additional health benefits. Such as reducing the risk of heart failure and kidney complications, which are common in people with diabetes.
Effectiveness in Blood Sugar Control
Both medications are effective at lowering blood sugar, but there are slight differences in their overall impact.
Farxiga (Dapagliflozin):
Farxiga has demonstrated a significant reduction in HbA1c levels (a key measure of long-term blood sugar control). This is typically by about 0.7% to 1% when used alone or with other medications.
This medication also offers modest weight loss, typically between 2-4 kg (4-9 lbs). For patients with type 2 diabetes who are overweight or obese, this can be a useful benefit.
Farxiga is also shown to improve cardiovascular health, especially in patients with type 2 diabetes and heart failure. This can further support long-term health.
Invokana (Canagliflozin):
Invokana also effectively reduces HbA1c levels, with reductions of around 0.8% to 1% on average. Weight loss is another benefit of Invokana, with typical reductions of 3-5 kg (6-11 lbs). This is somewhat greater than Farxiga’s effect.
Invokana is particularly well-known for its benefits in preventing cardiovascular events. It has been shown to reduce the risk of:
- heart attack
- stroke
- cardiovascular death in high-risk diabetic patients
This makes it an attractive option for those with existing heart disease.
Cardiovascular and Kidney Benefits
An important distinction between Farxiga and Invokana is their impact on heart and kidney health.
Farxiga:
Farxiga has been proven to significantly reduce the risk of hospitalization due to heart failure and to slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes. The DAPA-HF trial found that Farxiga reduced the risk of cardiovascular death and hospitalization for heart failure.
It is also approved for use in patients with kidney disease, even those without diabetes, to slow the decline of kidney function. Make sure to consult an expert when it comes to using Farxiga.
Invokana:
Invokana has demonstrated a similar reduction in cardiovascular risks, including a decrease in:
- heart attacks
- strokes
- cardiovascular death
Especially in patients with type 2 diabetes who have cardiovascular disease.
The CANVAS trial showed that Invokana significantly reduced the risk of major cardiovascular events. It also reduces the progression of kidney disease, with benefits for patients who have diabetes-related kidney complications.
Start Comparing Farxiga vs Invokana Now
In conclusion, after analyzing the effectiveness and safety of Farxiga vs Invokana, it is clear that both medications have their own advantages and limitations. However, it is recommended to consult with a medical professional to determine the best option for individual needs. Take charge of your health and talk to your doctor today.
If you want to read more articles, visit our blog.
FURHTER READING
